Status:
UNKNOWN
Prostatic Artery Embolization in Advanced Prostate Cancer
Lead Sponsor:
Dominik Abt
Conditions:
Prostate Cancer
Bladder Outlet Obstruction
Eligibility:
MALE
Phase:
NA
Brief Summary
This is a pilot study assessing efficacy and safety in patients with advanced prostate cancer.
Detailed Description
PAE has been shown to be safe and effective in the treatment of prostatic bleeding and lower urinary tract symptoms arising from bladder outlet obstruction. Advanced (defined as locally advanced, met...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Advanced PCA (i.e., locally advanced, metastatic, combination of both. This includes T3-4, any T in case of N1 and any T in case of M1a/b/c)
- PAE is indicated for the treatment of Lower urinary tract symptoms like bladder outlet obstruction or recurrent prostatic bleeding.
- IPSS at baseline ≥ 8
- Witten informed consent
- Exclusion Criteria:
- Curative treatment of PCA intended
- Contraindications for MRI
- Renal impairment (GFR \< 30ml/min)
- Allergy to i.v. contrast medium
- Vascular conditions that seem to make successful PAE impossible (e.g. severe atherosclerosis, severe tortuosity in the aortic bifurcation or internal iliac vessels)
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
- Drug-treatments for advanced prostate cancer (e.g., hormonal therapy or chemotherapy) established within 30 days prior to PAE.
Exclusion
Key Trial Info
Start Date :
March 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 2 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03457805
Start Date
March 2 2018
End Date
August 2 2021
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cantonal Hospital St. Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland, 9007